Advertisement
Advertisement
June 4, 2025
TriSalus Launches TriNav FLX Infusion System
June 4, 2025—TriSalus Life Sciences, Inc. announced the launch of its TriNav FLX infusion system, the latest addition to the company’s TriNav portfolio of pressure-enabled drug delivery devices for interventional treatment of tumors.
According to the company, TriNav FLX provides enhanced trackability and more options for interventionalists. Compared to previous TriNav systems, this new system features twice the length and more flexible material at the distal end, allowing for easier navigation through more tortuous vessels in challenging peripheral vascular anatomy. Additionally, TriSalus stated that TriNav FLX provides a 28% reduction in force during navigation compared to the standard TriNav design, as demonstrated in benchtop models.
The company advised that the TriNav FLX is eligible for reimbursement under the Centers for Medicare & Medicaid Services Healthcare Common Procedure Coding System code C8004 for simulation—or mapping—as well as code C9797 for treatment procedures. This dual coverage allows clinicians to use TriNav FLX for both planning and delivery in radioembolization, noted TriSalus.
TriSalus stated it seeks to integrate its delivery technology with standard-of-care therapies and its investigational immunotherapy.
Advertisement
Advertisement
